Citations

Clear

4610 citation(s) found for "Lu, Brian".

Autologous haematopoietic cell transplantation for non‐Hodgkin lymphoma with secondary CNS involvement
Wang, Zhiwei , Zhang, Mei‐Jie , Bolwell, Brian J., Chen, Andy I. , Fenske, Timothy S. , Freytes, César O. , Gibson, John, Hayes‐Lattin, Brandon , Holmberg, Leona , Inwards, David J. , Isola, Luis , Khoury, H. Jean , Lewis, Victor , Maharaj, Dipnarine , Munker, Reinhold , Phillips, Gordon L., Rizzieri, David A. , Rowlings, Philip A., Saber, Wael , Satwani, Prakash , Waller, Edmund K. , Maloney, David G. , Montoto, Silvia , Laport, Ginna G. , Hari, Parameswaran , Holmberg, Leona , Chen, Andy , Maziarz, Richard Thomas , Gale, Robert Peter , Vose, Julie M. , Lazarus, Hillard M. , Waller, Edmund K , Montoto, Silvia , Hari, Parameswaran

Mayo Clinic

British Journal of Haematology | July 6, 2013 | Volume: 162 | Issue: 5 | Pages: 648-656

10.1111/bjh.12451 | PMID 23829536 Get It

SummaryPre‐existing central nervous system (CNS) involvement may influence referral for autologous haematopoietic cell transplantation (AHCT) for patients with non‐Hodgkin lymphoma (NHL). The outcomes of 151 adult patients with NHL with prior secondary CNS involvement (CNS+) receiving an AHCT were compared to 4688 patients without prior CNS lymphoma (CNS−). There were significant baseline differences between the cohorts. CNS+ patients were more likely to be younger, have lower performance scores, higher age‐adjusted international prognostic index scores, more advanced disease stage at diagnosis, more aggressive histology, more sites of extranodal disease, and a shorter interval between diagnosis and AHCT. However, no statistically significant differences were identified between the two groups by analysis of progression‐free survival (PFS) and overall survival (OS) at 5 years. A matched pair comparison of the CNS+ group with a subset of CNS− patients matched on propensity score also showed no differences in outcomes. Patients with active CNS lymphoma at the time of AHCT (n = 55) had a higher relapse rate and diminished PFS and OS compared with patients whose CNS lymphoma was in remission (n = 96) at the time of AHCT. CNS+ patients can achieve excellent long‐term outcomes with AHCT. Active CNS lymphoma at transplant confers a worse prognosis.
Cardiac Device Complications in the Cognitively Impaired
Jama, Abdi, Hodge, David O. , Herges, Regina M., Asirvatham, Samuel, Cha, Yong‐Mei , Powell, Brian D. , Rea, Robert F., Friedman, Paul A. , Asirvatham, Samuel J. , Rabinstein, Alejandro A. , Asirvatham, Samuel J

Mayo Clinic

Pacing and Clinical Electrophysiology | July 4, 2013 | Volume: 36 | Issue: 9 | Pages: 1061-1067

10.1111/pace.12205 | PMID 23822919 Get It

BackgroundPatients with preexisting mild cognitive impairment or dementia may be at increased risk for developing cardiac device complications due to an impaired ability to follow postimplant care instructions. We sought to determine whether rates of infection, lead dislodgement, or appropriate or inappropriate implantable cardioverter defibrillator (ICD) shocks are increased in this population.MethodsMedical charts of 561 patients with mild cognitive impairment or dementia who underwent pacemaker (PM) or ICD implantation between January 2002 and October 2009 at Mayo Clinic were identified. A total of 134 patients who were diagnosed with cognitive impairment or dementia before device implantation or within 1 year of implantation were compared with 134 matched controls. Information was collected on patient characteristics, comorbid medical conditions, ejection fraction, complications, device type, device therapy, and mortality. Device information was prospectively entered into a database and retrospectively reviewed.ResultsOf the 134 patients with mild cognitive impairment and dementia, 99 underwent PM implantation and 35 underwent ICD implantation. Compared to controls, there was no difference in patient characteristics, ejection fraction, or comorbidities except for diabetes, which was more prevalent in the cognitively impaired and demented group (18.7% vs 30.6%, P = 0.02). There was no difference in device therapy and complications (14.4% vs 5.8%, P = 0.268). However, there was a decreased survival in patients with cognitive impairment and dementia when compared to the control group (42% vs 67% at 5 years, P = 0.007).ConclusionPatients with cognitive impairment and standard device indications are not at increased risk for device complications and therapy but their survival is much lower than in matched controls. The cause of this lower survival is unknown but may be related to the underlying neurological disease. Presence of cognitive impairment should therefore be considered when contemplating implantation of a cardiac device.
Nitrofurantoin-Induced Granulomatous Interstitial Pneumonia
Sakata, Kenneth K. , Larsen, Brandon T. , Boland, Jennifer M. , Palen, Brian N., Muhm, John R., Helmers, Richard A. , Tazelaar, Henry D. , Palen, Brian, Tazelaar, Henry D.

Mayo Clinic

International Journal of Surgical Pathology | June 28, 2013 | Volume: 22 | Issue: 4 | Pages: 352-357

10.1177/1066896913492849 | PMID 23812013 Get It

Nitrofurantoin-induced lung toxicity is relatively common, but rare histologic patterns sometimes occur that may make diagnosis difficult. We present the case of a 69-year-old woman taking prophylactic nitrofurantoin for urinary tract infections, who developed granulomatous interstitial pneumonia. She improved with cessation of nitrofurantoin, without other therapy. To our knowledge, this is the fourth reported case of granulomatous interstitial pneumonia associated with nitrofurantoin, and the first to show complete resolution with cessation of the drug alone, without steroids. It is important to recognize that idiosyncratic reactions to nitrofurantoin can produce a wide spectrum of histologic patterns. Of these patterns, granulomatous interstitial pneumonia is a rarely evidenced manifestation (possibly because few cases undergo a confirmatory lung biopsy). Recognition of granulomatous interstitial pneumonia as a manifestation of nitrofurantoin toxicity can aid in early identification of the reaction and prompt withdrawal of the drug, both of which are essential to prevent long-term complications.
MR elastography derived shear stiffness-a new imaging biomarker for the assessment of early tumor response to chemotherapy
Pepin, Kay , Glaser, Kevin J. , Mariappan, Yogesh K. , Reuland, Brian, Ziesmer, Steven C., Carter, Rickey E. , Ansell, Stephen M. , McGee, Kiaran P. , Chen, Jun , Ehman, Richard L. , Carter, Rickey E , Mariappan, Yogesh Kannan

Mayo Clinic

Magnetic Resonance in Medicine | June 25, 2013 | Volume: 71 | Issue: 5 | Pages: 1834-1840

10.1002/mrm.24825 | PMID 23801372 Get It

Eligibility for neoadjuvant/adjuvant cisplatin‐based chemotherapy among radical cystectomy patients
Thompson, R. Houston, Boorjian, Stephen A. , Kim, Simon P. , Cheville, John C. , Thapa, Prabin , Tarrel, Robert, Dronca, Roxana , Costello, Brian A. , Frank, Igor

Mayo Clinic

BJU International | June 13, 2013 | Volume: 113 | Issue: 5b | Pages: No page available

10.1111/bju.12274 | PMID 24006893 Get It

Objective To determine renal function eligibility for cisplatin‐based chemotherapy using our experience with radical cystectomy ( RC ) patients. Patients and Methods Using the M ayo C linic C ystectomy R egistry, we identified 768 patients treated with RC without neoadjuvant chemotherapy for urothelial carcinoma from 1980–2005. Glomerular filtration rate ( GFR ) was estimated using the C hronic K idney D isease E pidemiology C ollaboration ( CKD‐EPI ) equation and a value of ≥60 mL/min was considered eligible for cisplatin‐based chemotherapy. Factors associated with change in GFR (from preoperative to 3‐month postoperative) were assessed using linear regression. Results The median age was 68 years, while the median GFR was 60 mL/min both preoperatively and 3 months after RC . Overall, 405 (53%) patients had a GFR of <60 mL/min before surgery and 387 (50%) had a GFR of <60 mL/min at 3 months after RC . Patients with hydronephrosis (209 patients) had significantly lower preoperative GFRs than with patients without hydronephrosis (median 52 vs 62 mL/min, respectively; P < 0.001). Among the 363 patients with a GFR of ≥60 mL/min before RC , 91 (25%) had a decline in renal function to a GFR of <60 mL/min at 3 months after RC . In multivariable analyses, older age ( P < 0.001), higher preoperative GFR ( P < 0.001) and continent urinary diversion ( P = 0.011) were significantly associated with a negative change in GFR after RC . Conclusions Our results suggest that nearly half of patients undergoing RC are not eligible to receive perioperative cisplatin‐based chemotherapy based on renal function status. About a quarter of patients eligible for cisplatin before surgery are no longer eligible after RC . Certain patient characteristics and surgical factors are more likely to experience a negative change in GFR after RC and should be counselled accordingly.
Impact of fasting on human brain acid‐base homeostasis using natural abundance 13C and 31P MRS
Sailasuta, Napapon, Harris, Kent, Tran, Thao , Ross, Brian D. , Abulseoud, Osama A.

Mayo Clinic

Journal of Magnetic Resonance Imaging | June 3, 2013 | Volume: 39 | Issue: 2 | Pages: 398-401

10.1002/jmri.24166 | PMID 23733582 Get It

PurposeTo use 13C magnetic resonance spectroscopy (MRS) and 31P MRS to develop a direct assay for regional [HCO3−] in the human brain and to define brain pH and physiological response of [HCO3−] to fasting.Materials and MethodsSeven healthy subjects underwent MRS examinations on a 1.5T MRI scanner. Subjects were well fed with repeated examinations performed after 4 and 12 hours of fasting. Proton noise decoupling 13C MRS were acquired using pulse and acquired acquisition while 31P MRS were acquired using a 2D chemical shift imaging method with relaxation time (TR) of 2 seconds.ResultsFasting brain bicarbonate concentrations (6.7 ± 2.5 mM for 12‐hour fasting, P = 0.002 and 8.3 ± 2.1 mM for 4‐hour fasting, P = 0.015) are significantly reduced compared to fed state (11.6 ± 1.3 mM). However, no significant difference in brain pH was observed, confirming the critical role of pCO2 in intracerebral pH homeostasis.ConclusionWe demonstrated that the intracellular HCO3− in human brain is readily modified by diet but appears to have no measurable effect on cerebral pH. Natural abundance 13C can provide useful information relevant to human brain pH homeostasis by providing information for HCO3−. J. Magn. Reson. Imaging 2014;39:398–401. © 2013 Wiley Periodicals, Inc.
Prospective Assessment of Dynamic CT and MR Cholangiography in Functional Biliary Pain
Fidler, Jeff L. , Knudsen, John M. , Collins, Douglas A. , McGee, Kiaran P. , Lahr, Brian D. , Thistle, Johnson L., Topazian, Mark , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | May 31, 2013 | Volume: 201 | Issue: 2 | Pages: W271-W282

10.2214/ajr.12.9538 | PMID 23724800 Get It

The Impact of Histological Reclassification during Pathology Re-Review—Evidence of a Will Rogers Effect in Bladder Cancer?
Linder, Brian J. , Boorjian, Stephen A. , Cheville, John C. , Sukov, William R. , Thapa, Prabin , Tarrell, Robert F., Frank, Igor, Linder, Brian J

Mayo Clinic

Journal of Urology | May 23, 2013 | Volume: 190 | Issue: 5 | Pages: 1692-1697

10.1016/j.juro.2013.05.040 | PMID 23707452 Get It

TROY (TNFRSF19) Promotes Glioblastoma Survival Signaling and Therapeutic Resistance
Loftus, Joseph C. , Tuncali, Serdar, Kloss, Jean , Schumacher, Cassie, Cao, Brian, Williams, Bart O. , Eschbacher, Jennifer , Ross, Julianna T.D., Tran, Nhan L. , Dhruv, Harshil , Yang, Zhongbo , Tran, Nhan L

Mayo Clinic

Molecular Cancer Research | May 23, 2013 | Volume: 11 | Issue: 8 | Pages: 865-874

10.1158/1541-7786.mcr-13-0008 | PMID 23699535 Get It

Abstract Of the features that characterize glioblastoma, arguably none is more clinically relevant than the propensity of malignant glioma cells to aggressively invade into the surrounding normal brain tissue. These invasive cells render complete resection impossible, confer significant resistance to chemo- and radiation-therapy, and virtually assure tumor recurrence. Expression of TROY (TNFRSF19), a member of the TNF receptor superfamily, inversely correlates with patient survival and stimulates glioblastoma cell migration and invasion in vitro. In this study, we report that TROY is overexpressed in glioblastoma tumor specimens and TROY mRNA expression is increased in the invasive cell population in vivo. In addition, inappropriate expression of TROY in mouse astrocytes in vivo using glial-specific gene transfer in transgenic mice induces astrocyte migration within the brain, validating the importance of the TROY signaling cascade in glioblastoma cell migration and invasion. Knockdown of TROY expression in primary glioblastoma xenografts significantly prolonged survival in vivo. Moreover, TROY expression significantly increased resistance of glioblastoma cells to both IR- and TMZ-induced apoptosis via activation of Akt and NF-κB. Inhibition of either Akt or NF-κB activity suppressed the survival benefits of TROY signaling in response to TMZ treatment. These findings position aberrant expression and/or signaling by TROY as a contributor to the dispersion of glioblastoma cells and therapeutic resistance. Implications: Targeting of TROY may increase tumor vulnerability and improve therapeutic response in glioblastoma. Mol Cancer Res; 11(8); 865–74. ©2013 AACR.
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
Terpos, Evangelos , Morgan, Gareth J. , Dimopoulos, Meletios Α. , Lentzsch, Suzanne , Sezer, Orhan , García‐Sánz, Ramón , Shimizu, Kazuyuki , Turesson, Ingemar , Reiman, Tony , Merlini, Giampaolo , Spencer, Andrew , Leleu, Xavier , Cavo, Michèle , Munshi, Nikhil C. , Durie, Brian G.M. , Roodman, G. David, Drake, Matthew T. , Raje, Noopur , Jurczyszyn, Artur , Rajkumar, S. Vincent , Merlini, Giampaolo , Dimopoulos, Meletios A , Terpos, Evangelos , Garcia-Sanz, Ramon , Morgan, Gareth J

Mayo Clinic

Journal of Clinical Oncology | May 21, 2013 | Volume: 31 | Issue: 18 | Pages: 2347-2357

10.1200/jco.2012.47.7901 | PMID 23690408 Get It

Purpose The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) –related bone disease. Methodology An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. Recommendations Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.